Zimmer, Mary
Zimmer, Mary was paid $561K by Medicaid between Apr 2023 and Nov 2024, across 22 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoZIMMER, MARY
MURPHYSBORO, IL 62966
MURPHYSBORO, IL 62966
33aNPI1871042648assigned 09/22/2016
33bProvider typeRegistered Nurse
28Total paid$561K
24GClaims14,567
24DCodes billed22
24AFirst – last monthApr 2023 – Nov 2024
Compared with peers
Next to other Registered Nurse providers in Illinois
Rank by total paid#13 of 486
Median peer was paid$19K
This provider vs. median29×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 6,105 | $232K | |
| 2024incomplete | 8,462 | $329K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 2,574 | 2,389 | $173K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 1,957 | 1,795 | $89K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 15% | 1,120 | 1,082 | $87K |
| 99000 | 7.6% | 1,900 | 1,740 | $42K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 7.2% | 1,186 | 1,061 | $41K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 7.1% | 857 | 817 | $40K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.0% | 1,287 | 1,028 | $33K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.1% | 1,125 | 997 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 154 | 114 | $8K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.2% | 169 | 118 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 78 | 58 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 158 | 134 | $5K |
10 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 438 | $5K |
| 87428 | <1% | 57 | $4K | |
| 87210 | <1% | 463 | $2K | |
| 81002 | <1% | 549 | $1K | |
| 87807 | <1% | 81 | $796.02 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 178 | $384.55 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 58 | $285.20 |
| 81025 | <1% | 51 | $242.99 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 59 | $58.47 |
| 36415 | Collection of venous blood by venipuncture | <1% | 68 | $6.18 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.